In the News
June 22, 2018 / News Page
Charles G. Drake, MD, PhD, professor of medical oncology at New York Presbyterian/Columbia University Medical Center, discusses his thoughts on whether sunitinib would be more successful as a treatment for patients with renal cell carcinoma if used in the neoadjuvant setting. He debates whether immunotherapies or neoadjuvant therapies would be more useful.Read More
June 20, 2018 / News Page
CLICK HERE TO READ THE FULL ARTICLERead More
March 7, 2017 / News Page
Congressionally-directed Medical Research Program. It took over a decade of hard work from kidney cancer advocates to obtain kidney cancer-specific research funding included in the federal budget. Nevertheless, in March of 2017 Congress approved and the president signed the Consolidation Appropriations Act.Read More
Funded major projects to date include:
RADVAX investigator led immunotherapy trial for 25 advanced kidney cancer patients at UT Southwestern combining Nivolumab, Ipilimumab and SBRT.
Support of UT Southwestern’s Kidney Cancer Research Program. 1 of only 2 SPOREs (Specialized Programs of Research Excellence) for Kidney Cancer in the US.
Our primary sources of support are donations from the general public and fundraising.
Stay in Touch: Join The Kidney Cancer Coalition Email List!
Please enter your information below: